ABIONYX Pharma SA (ENXTPA: ABNX)
Health Care · Biotechnology · FR
€1.62
-8.88% today · -52.8% 1Y
ABIONYX Pharma SA (ENXTPA: ABNX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $77.29M and employs 49 people.
Over the last twelve months the share price has lost 52.8%, trading between 1.61 and 5.29.
Tweenvest scores ABIONYX Pharma SA across four factors: quality 36/100, value 59/100. Its strongest factor is value.
ABNX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $77.29M
- Revenue (TTM)
- $4.77M
- P/E
- —
- EPS
- -0.16
- Dividend yield
- —
- Beta (5Y)
- 0.47
- 52-week high
- €5.29
- 52-week low
- €1.61
- Avg volume (3M)
- —
- Shares outstanding
- 42.34M
- Employees
- 49
- Next earnings
- —
About ABIONYX Pharma SA
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.
- ISIN
- FR0012616852
- Founded
- 2005
- Listed since
- Mar 30, 2015
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Brii Biosciences LimitedSEHK: 2137 | $79.11M | HK$0.86 | -3.37% |
| Pelthos Therapeutics Inc.NYSEAM: PTHS | $78.87M | $20.50 | -0.49% |
| Wuhan YZY Biopharma Co., Ltd.SEHK: 2496 | $78.80M | HK$3.19 | -0.31% |
| Nordicus Partners CorporationOTCPK: NORD | $77.95M | $4.01 | +13.89% |
| OKYO Pharma LimitedNasdaqCM: OKYO | $77.14M | $1.39 | -5.44% |
| Covalon Technologies Ltd.TSXV: COV | $77.11M | CA$3.98 | 0.00% |
| Sensorion SAENXTPA: ALSEN | $76.66M | €5.90 | -10.74% |
| CORESTEMCHEMON Inc.KOSDAQ: A166480 | $76.25M | ₩2,315.00 | +8.94% |
Figures last refreshed Oct 4, 2026.